Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905613 | 0.94 | HDAC1 (0.54) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13846317 | 0.84 | HDAC1 (0.57) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL978192 | 0.83 | HDAC1 (0.56) | HDAC1HDAC6KDM4ENPC1RAB9A | |
| SCHEMBL13850954 | 0.77 | P4HTM (0.70) | PTGESP4HTMPTGS2 | |
| SCHEMBL6972046 | 0.76 | HDAC1 (0.77) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL5903774 | 0.76 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL8567491 | 0.74 | HDAC1 (0.77) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL359879 | 0.72 | KDM4E (0.73) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL27623934 | 0.71 | KDM4E (0.77) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL26054492 | 0.71 | KDM4E (0.67) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | claimed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | claimed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | claimed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | HDAC1 2889/4885HDAC3 1983/4885HDAC4 3207/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | HDAC1 2735/4885HDAC3 2511/4885HDAC4 3776/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | HDAC1 2735/4885HDAC3 2511/4885HDAC4 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.